nach oben

Modern Rheumatology

Erschienen in:

01.06.2009 | Original Article

Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity

verfasst von: Ayako Hayashi, Hiroko Nagafuchi, Ichiaki Ito, Koichi Hirota, Michiteru Yoshida, Shoichi Ozaki

Erschienen in: Modern Rheumatology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

The high mobility group box 1 (HMGB1) protein is a non-histone chromosomal protein that acts as a potent proinflammatory cytokine when actively secreted from LPS- or TNF-activated macrophages, monocytes, and other cells. Anti-HMGB1/2 antibodies have been previously identified in sera from a high proportion of patients with autoimmune diseases. In this study, we examined anti-HMGB1 antibody titers in sera of patients with systemic rheumatic diseases and the correlations between the presence of anti-HMGB1 antibodies and disease activity in systemic lupus erythematosus (SLE) patients by enzyme-linked immunosorbent assay and western blotting. We detected increases in both the levels and the frequency of anti-HMGB1 antibodies in sera from SLE and polymyositis/dermatomyositis (PM/DM) patients, and observed that the presence of anti-HMGB1 antibodies positively correlates with SLE disease activity index. Through epitope mapping, we found that multiple HMGB1 epitopes were recognised in SLE sera, with the major epitope mapping to box A. Another epitope, the joiner region of HMGB1, was preferentially recognized by SLE sera, but not by PM/DM sera. Collectively, these observations suggest that the presence of anti-HMGB1 antibodies correlates with disease activity in SLE patients.

Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345:340–50.PubMedCrossRef

Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, et al. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol. 2007;81:67–74.PubMedCrossRef

Bustin M, Lehn DA, Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta. 1990;1049:231–43.PubMed

Majumdar A, Brown D, Kerby S, Rudzinski I, Polte T, Randhawa Z, et al. Sequence of human HMG2 cDNA. Nucleic Acids Res. 1991;19:6643.PubMedCrossRef

Wen L, Huang JK, Johnson BH, Reeck GR. A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1. Nucleic Acids Res. 1989;17:1197–214.PubMedCrossRef

Shirakawa H, Yoshida M. Structure of a gene coding for human HMG2 protein. J Biol Chem. 1992;267:6641–5.PubMed

Shirakawa H, Tsuda K, Yoshida M. Primary structure of non-histone chromosomal protein HMG2 revealed by the nucleotide sequence. Biochemistry. 1990;29:4419–23.PubMedCrossRef

Uesugi H, Ozaki S, Sobajima J, Osakada F, Shirakawa H, Yoshida M, et al. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J Rheumatol. 1998;25:703–9.PubMed

Ayer LM, Rubin RL, Dixon GH, Fritzler MJ. Antibodies to HMG proteins in patients with drug-induced autoimmunity. Arthritis Rheum. 1994;37:98–103.PubMedCrossRef

10.

Neuer G, Bustin M, Michels H, Truckenbrodt H, Bautz FA. Autoantibodies to the chromosomal protein HMG-17 in juvenile rheumatoid arthritis. Arthritis Rheum. 1992;35:472–5.PubMedCrossRef

11.

Wittemann B, Neuer G, Michels H, Truckenbrodt H, Bautz FA. Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1990;33:1378–83.PubMedCrossRef

12.

Burlingame RW, Rubin RL, Rosenberg AM. Autoantibodies to chromatin components in juvenile rheumatoid arthritis. Arthritis Rheum. 1993;36:836–41.PubMedCrossRef

13.

Ayer LM, Senecal JL, Martin L, Dixon GH, Fritzler MJ. Antibodies to high mobility group proteins in systemic sclerosis. J Rheumatol. 1994;21:2071–5.PubMed

14.

Taira T, Matsuyama W, Mitsuyama H, Kawahara KI, Higashimoto I, Maruyama I, et al. Increased serum high mobility group box-1 level in Churg–Strauss syndrome. Clin Exp Immunol. 2007;148:241–7.

15.

Ma W, Ozaki S, Sobajima J, Uesugi H, Murakami M, Tanaka M, et al. Detection of anti-neutrophil cytoplasmic antibodies in MRL/Mp-lpr/lpr mice and analysis of their target antigens. Autoimmunity. 2000;32:281–91.PubMedCrossRef

16.

Sobajima J, Ozaki S, Uesugi H, Osakada F, Inoue M, Fukuda Y, et al. High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis. Gut. 1999;44:867–73.PubMedCrossRef

17.

Sobajima J, Ozaki S, Osakada F, Uesugi H, Shirakawa H, Yoshida M, et al. Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2. Clin Exp Immunol. 1997;107:135–40.PubMedCrossRef

18.

Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191–5.PubMedCrossRef

19.

Hunter P. Sepsis under siege: a new understanding of sepsis might lead to the development of therapies to treat septic shock. EMBO Rep. 2006;7:667–9.PubMedCrossRef

20.

Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–51.PubMedCrossRef

21.

Chen G, Li J, Ochani M, Rendon-Mitchell B, Qiang X, Susarla S, et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol. 2004;76:994–1001.PubMedCrossRef

22.

Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol. 2003;170:3890–7.PubMed

23.

Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery. 1999;126:389–92.PubMed

24.

Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–42.PubMedCrossRef

25.

Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279:7370–7.PubMedCrossRef

26.

Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 2002;62:4805–11.PubMed

27.

Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003;48:971–81.PubMedCrossRef

28.

Sanford AN, Dietzmann K, Sullivan KE. Apoptotic cells, autoantibodies, and the role of HMGB1 in the subcellular localization of an autoantigen. J Autoimmun. 2005;25:264–71.PubMedCrossRef

29.

Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M, et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 2005;52:3639–45.PubMedCrossRef

30.

Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8:487–96.PubMedCrossRef

31.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.PubMedCrossRef

32.

Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol. 1991;18:1180–4.PubMed

33.

Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 2004;50:1586–94.PubMedCrossRef

34.

Adachi Y, Mizuno S, Yoshida M. Efficient large-scale purification of non-histone chromosomal proteins HMG1 and HMG2 by using Polybuffer-exchanger PBE94. J Chromatogr. 1990;530:39–46.PubMedCrossRef

35.

Ito I, Mitsuoka N, Sobajima J, Uesugi H, Ozaki S, Ohya K, et al. Conformational difference in HMGB1 proteins of human neutrophils and lymphocytes revealed by epitope mapping of a monoclonal antibody. J Biochem (Tokyo). 2004;136:155–62.

36.

Kirkley JE, Goldstein AL, Naylor PH. Effect of peptide-carrier coupling on peptide-specific immune responses. Immunobiology. 2001;203:601–15.PubMed

37.

Rose BG, Kamps-Holzapple C, Stanker LH. Competitive indirect ELISA for ceftiofur sodium and the effect of different immunizing and coating antigen conjugates. Bioconjug Chem. 1995;6:529–35.PubMedCrossRef

38.

Routsias JG, Tzioufas AG, Moutsopoulos HM. The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. Clin Chim Acta. 2004;340:1–25.PubMedCrossRef

39.

Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett. 2008;121:61–73.PubMedCrossRef

40.

Elkon K, Bonfa E, Llovet R, Danho W, Weissbach H, Brot N. Properties of the ribosomal P2 protein autoantigen are similar to those of foreign protein antigens. Proc Natl Acad Sci USA. 1988;85:5186–9.PubMedCrossRef

41.

Chan EK, Tan EM. Epitopic targets for autoantibodies in systemic lupus erythematosus and Sjogren’s syndrome. Curr Opin Rheumatol. 1989;1:376–81.PubMedCrossRef

42.

Dohlman JG, Lupas A, Carson M. Long charge-rich alpha-helices in systemic autoantigens. Biochem Biophys Res Commun. 1993;195:686–96.PubMedCrossRef

43.

Baxevanis AD, Landsman D. The HMG-1 box protein family: classification and functional relationships. Nucleic Acids Res. 1995;23:1604–13.PubMedCrossRef

44.

Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol. 2005;26:381–7.PubMedCrossRef

45.

Weir HM, Kraulis PJ, Hill CS, Raine AR, Laue ED, Thomas JO. Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 1993;12:1311–9.PubMed

46.

van Venrooij WJ, van Gelder CW. B cell epitopes on nuclear autoantigens. What can they tell us? Arthritis Rheum. 1994;37:608–16.PubMedCrossRef

47.

Scannell DR, Frank AC, Conant GC, Byrne KP, Woolfit M, Wolfe KH. Independent sorting-out of thousands of duplicated gene pairs in two yeast species descended from a whole-genome duplication. Proc Natl Acad Sci USA. 2007;104:8397–402.PubMedCrossRef

48.

Krause A, Ramakumar A, Bartels D, Battistoni F, Bekel T, Boch J, et al. Complete genome of the mutualistic, N₂-fixing grass endophyte Azoarcus sp. strain BH72. Nat Biotechnol. 2006;24:1385–91.PubMedCrossRef

49.

Chen XH, Koumoutsi A, Scholz R, Eisenreich A, Schneider K, Heinemeyer I, et al. Comparative analysis of the complete genome sequence of the plant growth-promoting bacterium Bacillus amyloliquefaciens FZB42. Nat Biotechnol. 2007;25:1007–14.PubMedCrossRef

50.

Dietrich FS, Voegeli S, Brachat S, Lerch A, Gates K, Steiner S, et al. The Ashbya gossypii genome as a tool for mapping the ancient Saccharomyces cerevisiae genome. Science. 2004;304:304–7.PubMedCrossRef

51.

Bruggemann H, Baumer S, Fricke WF, Wiezer A, Liesegang H, Decker I, et al. The genome sequence of Clostridium tetani, the causative agent of tetanus disease. Proc Natl Acad Sci USA. 2003;100:1316–21.PubMedCrossRef

52.

Matsunaga T, Okamura Y, Fukuda Y, Wahyudi AT, Murase Y, Takeyama H. Complete genome sequence of the facultative anaerobic magnetotactic bacterium Magnetospirillum sp. strain AMB-1. DNA Res. 2005;12:157–66.PubMedCrossRef

53.

Shirai T, Suzuki A, Yamane T, Ashida T, Kobayashi T, Hitomi J, et al. High-resolution crystal structure of M-protease: phylogeny aided analysis of the high-alkaline adaptation mechanism. Protein Eng. 1997;10:627–34.PubMedCrossRef

54.

Dujon B, Sherman D, Fischer G, Durrens P, Casaregola S, Lafontaine I, et al. Genome evolution in yeasts. Nature. 2004;430:35–44.PubMedCrossRef

55.

Caldwell RB, Kierzek AM, Arakawa H, Bezzubov Y, Zaim J, Fiedler P, et al. Full-length cDNAs from chicken bursal lymphocytes to facilitate gene function analysis. Genome Biol. 2005;6:R6.PubMedCrossRef

56.

Pohlmann A, Fricke WF, Reinecke F, Kusian B, Liesegang H, Cramm R, et al. Genome sequence of the bioplastic-producing “Knallgas” bacterium Ralstonia eutropha H16. Nat Biotechnol. 2006;24:1257–62.PubMedCrossRef

57.

Joardar V, Lindeberg M, Jackson RW, Selengut J, Dodson R, Brinkac LM, et al. Whole-genome sequence analysis of Pseudomonas syringae pv. phaseolicola 1448A reveals divergence among pathovars in genes involved in virulence and transposition. J Bacteriol. 2005;187:6488–98.

58.

Yu J, Wang J, Lin W, Li S, Li H, Zhou J, et al. The genomes of Oryza sativa: a history of duplications. PLoS Biol. 2005;3:e38.PubMedCrossRef

59.

Zhang YQ, Ren SX, Li HL, Wang YX, Fu G, Yang J, et al. Genome-based analysis of virulence genes in a non-biofilm-forming Staphylococcus epidermidis strain (ATCC 12228). Mol Microbiol. 2003;49:1577–93.PubMedCrossRef

60.

von Landenberg P, Lehmann HW, Modrow S. Human parvovirus B19 infection and antiphospholipid antibodies. Autoimmun Rev. 2007;6:278–85.CrossRef

61.

McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med. 2005;11:85–9.PubMedCrossRef

Titel: Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity
verfasst von: Ayako Hayashi
Hiroko Nagafuchi
Ichiaki Ito
Koichi Hirota
Michiteru Yoshida
Shoichi Ozaki
Publikationsdatum: 01.06.2009
Verlag: Springer Japan
Erschienen in: Modern Rheumatology / Ausgabe 3/2009
Print ISSN: 1439-7595
Elektronische ISSN: 1439-7609
DOI: https://doi.org/10.1007/s10165-009-0151-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases

Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases

Time of initial appearance of renal symptoms in the course of systemic lupus erythematosus as a prognostic factor for lupus nephritis

Sixty percent of patients with rheumatoid arthritis in Japan have used dietary supplements or health foods

Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab